-
1
-
-
0030962574
-
Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis
-
Chiba N, De Gara CJ, Wilkinson JM, et al,. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810.
-
(1997)
Gastroenterology
, vol.112
, pp. 1798-1810
-
-
Chiba, N.1
De Gara, C.J.2
Wilkinson, J.M.3
-
2
-
-
0141539363
-
Short-term treatment of gastroesophageal reflux disease
-
van Pinxteren B, Numans ME, Lau J, et al,. Short-term treatment of gastroesophageal reflux disease. J Gen Intern Med 2003; 18: 755-63.
-
(2003)
J Gen Intern Med
, vol.18
, pp. 755-763
-
-
Van Pinxteren, B.1
Numans, M.E.2
Lau, J.3
-
3
-
-
68949204296
-
Systematic review: Standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis - A mixed treatment comparison of randomized controlled trials
-
Edwards SJ, Lind T, Lundell L, et al,. Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis-a mixed treatment comparison of randomized controlled trials. Aliment Pharmacol Ther 2009; 30: 547-56.
-
(2009)
Aliment Pharmacol Ther
, vol.30
, pp. 547-556
-
-
Edwards, S.J.1
Lind, T.2
Lundell, L.3
-
4
-
-
14644421531
-
Efficacy of esomeprazole 40 mg vs. Lansoprazole 30 mg for healing moderate to severe erosive oesophagitis
-
Fennerty MB, Johanson JF, Hwang C, et al,. Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2005; 21: 455-63.
-
(2005)
Aliment Pharmacol Ther
, vol.21
, pp. 455-463
-
-
Fennerty, M.B.1
Johanson, J.F.2
Hwang, C.3
-
5
-
-
0034949404
-
The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: A 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety
-
Vakil NB, Shaker R, Johnson DA, et al,. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001; 15: 927-35.
-
(2001)
Aliment Pharmacol Ther
, vol.15
, pp. 927-935
-
-
Vakil, N.B.1
Shaker, R.2
Johnson, D.A.3
-
6
-
-
78649908709
-
Novel approaches to inhibition of gastric acid secretion
-
Sachs G, Shin JM, Hunt R,. Novel approaches to inhibition of gastric acid secretion. Curr Gastroenterol Rep 2010; 12: 437-47.
-
(2010)
Curr Gastroenterol Rep
, vol.12
, pp. 437-447
-
-
Sachs, G.1
Shin, J.M.2
Hunt, R.3
-
7
-
-
4344654345
-
Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: A randomized, three-way crossover study
-
Katz PO, Castell DO, Chen Y, et al,. Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study. Aliment Pharmacol Ther 2004; 20: 399-406.
-
(2004)
Aliment Pharmacol Ther
, vol.20
, pp. 399-406
-
-
Katz, P.O.1
Castell, D.O.2
Chen, Y.3
-
8
-
-
46749088691
-
Nocturnal gastroesophageal reflux disease: Issues, implications, and management strategies
-
Johnson DA, Katz PO,. Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies. Rev Gastroenterol Disord 2008; 8: 98-108.
-
(2008)
Rev Gastroenterol Disord
, vol.8
, pp. 98-108
-
-
Johnson, D.A.1
Katz, P.O.2
-
9
-
-
0037380492
-
Pharmacogenetics of the proton pump inhibitors: A systematic review
-
Chong E, Ensom MHH,. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 2003; 23: 460-71.
-
(2003)
Pharmacotherapy
, vol.23
, pp. 460-471
-
-
Chong, E.1
Ensom, M.H.H.2
-
10
-
-
25644459349
-
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies
-
Furuta T, Shirai N, Sugimoto M, et al,. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005; 20: 153-67.
-
(2005)
Drug Metab Pharmacokinet
, vol.20
, pp. 153-167
-
-
Furuta, T.1
Shirai, N.2
Sugimoto, M.3
-
11
-
-
28144433010
-
Potassium-competitive acid blockade: A new therapeutic strategy in acid-related diseases
-
Andersson K, Carlsson E,. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther 2005; 108: 294-307.
-
(2005)
Pharmacol Ther
, vol.108
, pp. 294-307
-
-
Andersson, K.1
Carlsson, E.2
-
12
-
-
0027053361
-
Comparison of once-daily intravenous and oral omeprazole on pentagastrin-stimulated acid secretion in duodenal ulcer patients
-
Cederberg C, Lind T, Röhss K, et al,. Comparison of once-daily intravenous and oral omeprazole on pentagastrin-stimulated acid secretion in duodenal ulcer patients. Digestion 1992; 53: 171-8.
-
(1992)
Digestion
, vol.53
, pp. 171-178
-
-
Cederberg, C.1
Lind, T.2
Röhss, K.3
-
13
-
-
0032737083
-
Pantoprazole versus omeprazole: Influence on meal-stimulated gastric acid secretion
-
Dammann HG, Burkhardt F,. Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion. Eur J Gastroenterol Hepatol 1999; 11: 1277-82.
-
(1999)
Eur J Gastroenterol Hepatol
, vol.11
, pp. 1277-1282
-
-
Dammann, H.G.1
Burkhardt, F.2
-
14
-
-
84861028397
-
Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methymethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB)
-
Arikawa Y, Nishida H, Kurasawa O, et al,. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methymethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem 2012; 55: 4446-56.
-
(2012)
J Med Chem
, vol.55
, pp. 4446-4456
-
-
Arikawa, Y.1
Nishida, H.2
Kurasawa, O.3
-
15
-
-
80054787732
-
Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol 3-yl]-N-methylmethanamine monofumarate (TAK-438)
-
Shin JM, Inatomi N, Munson K, et al,. Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol 3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther 2011; 339: 412-20.
-
(2011)
J Pharmacol Exp Ther
, vol.339
, pp. 412-420
-
-
Shin, J.M.1
Inatomi, N.2
Munson, K.3
-
16
-
-
79953716223
-
A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands
-
Matsukawa J, Hori Y, Nishida H, et al,. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol 2011; 81: 1145-51.
-
(2011)
Biochem Pharmacol
, vol.81
, pp. 1145-1151
-
-
Matsukawa, J.1
Hori, Y.2
Nishida, H.3
-
17
-
-
79956193494
-
A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals
-
Hori Y, Matsukawa J, Tekeuchi T, et al,. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther 2011; 337: 797-804.
-
(2011)
J Pharmacol Exp Ther
, vol.337
, pp. 797-804
-
-
Hori, Y.1
Matsukawa, J.2
Tekeuchi, T.3
-
18
-
-
77957228369
-
1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases
-
Hori Y, Imanishi A, Matsukawa J, et al,. 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther 2010; 335: 231-8.
-
(2010)
J Pharmacol Exp Ther
, vol.335
, pp. 231-238
-
-
Hori, Y.1
Imanishi, A.2
Matsukawa, J.3
-
19
-
-
37849036310
-
A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease
-
Dent J, Kahrilas PJ, Hatlebakk J, et al,. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol 2008; 103: 20-6.
-
(2008)
Am J Gastroenterol
, vol.103
, pp. 20-26
-
-
Dent, J.1
Kahrilas, P.J.2
Hatlebakk, J.3
-
20
-
-
84989307721
-
Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (Vonoprazan) doses in healthy male Japanese/non-Japanese subjects
-
Sakurai Y, Nishimura A, Kennedy G, et al,. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (Vonoprazan) doses in healthy male Japanese/non-Japanese subjects. Clin Transl Gastroenterol 2015; 6: e94. doi: 10.1038/ctg.2015.18
-
(2015)
Clin Transl Gastroenterol
, vol.6
, pp. e94
-
-
Sakurai, Y.1
Nishimura, A.2
Kennedy, G.3
-
21
-
-
84964207179
-
Randomised clinical trial: Safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects
-
Jenkins H, Sakurai Y, Nishimura A, et al,. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 2015; 41: 636-48.
-
(2015)
Aliment Pharmacol Ther
, vol.41
, pp. 636-648
-
-
Jenkins, H.1
Sakurai, Y.2
Nishimura, A.3
-
22
-
-
0029933079
-
The endoscopic assessment of esophagitis: A progress report on observer agreement
-
Armstrong D, Bennett JR, Blum AL, et al,. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 1996; 111: 85-92.
-
(1996)
Gastroenterology
, vol.111
, pp. 85-92
-
-
Armstrong, D.1
Bennett, J.R.2
Blum, A.L.3
-
23
-
-
0027973846
-
Mantel-Haenszel-type tests for testing equivalence or more than equivalence in comparative clinical trial
-
Yanagawa T, Tango T, Hiejima Y,. Mantel-Haenszel-type tests for testing equivalence or more than equivalence in comparative clinical trial. Biometrics 1994; 50: 859-64.
-
(1994)
Biometrics
, vol.50
, pp. 859-864
-
-
Yanagawa, T.1
Tango, T.2
Hiejima, Y.3
-
24
-
-
34848832890
-
A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD)
-
Kalaitzakis E, Björnsson E,. A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD). Ther Clin Risk Manag 2007; 3: 653-63.
-
(2007)
Ther Clin Risk Manag
, vol.3
, pp. 653-663
-
-
Kalaitzakis, E.1
Björnsson, E.2
-
25
-
-
10744220360
-
Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers
-
Yu KS, Bae KS, Shon JH, et al,. Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers. J Clin Pharmacol 2004; 44: 73-82.
-
(2004)
J Clin Pharmacol
, vol.44
, pp. 73-82
-
-
Yu, K.S.1
Bae, K.S.2
Shon, J.H.3
-
26
-
-
36549032595
-
A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis
-
Kahrilas PJ, Dent J, Luaritsen K, et al,. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol 2007; 5: 1385-91.
-
(2007)
Clin Gastroenterol Hepatol
, vol.5
, pp. 1385-1391
-
-
Kahrilas, P.J.1
Dent, J.2
Luaritsen, K.3
-
27
-
-
0026803020
-
Appropriate acid suppression for the management of gastro-oesophageal reflux disease
-
Bell NJV, Burget D, Howden CW, et al,. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51 (Suppl. 1): 59-67.
-
(1992)
Digestion
, vol.51
, pp. 59-67
-
-
Bell, N.J.V.1
Burget, D.2
Howden, C.W.3
-
28
-
-
67449088166
-
Epidemiology and clinical characteristics of GERD in the Japanese population
-
Fujiwara Y, Arakawa T,. Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol 2009; 44: 518-34.
-
(2009)
J Gastroenterol
, vol.44
, pp. 518-534
-
-
Fujiwara, Y.1
Arakawa, T.2
-
29
-
-
84879616935
-
Is proton pump inhibitor therapy for reflux esophagitis sufficient?: A large real-world survey of Japanese patients
-
Higuchi K, Joh T, Nakada K, et al,. Is proton pump inhibitor therapy for reflux esophagitis sufficient?: a large real-world survey of Japanese patients. Intern Med 2013; 52: 1447-54.
-
(2013)
Intern Med
, vol.52
, pp. 1447-1454
-
-
Higuchi, K.1
Joh, T.2
Nakada, K.3
-
30
-
-
84866234607
-
Gastric carcinoids after long-term use of a proton pump inhibitor
-
Jianu CS, Fossmark R, Viset T, et al,. Gastric carcinoids after long-term use of a proton pump inhibitor. Aliment Pharmacol Ther 2012; 36: 644-9.
-
(2012)
Aliment Pharmacol Ther
, vol.36
, pp. 644-649
-
-
Jianu, C.S.1
Fossmark, R.2
Viset, T.3
-
31
-
-
77953198919
-
Safety of the long-term use of proton pump inhibitors
-
Thomson AB, Sauve MD, Kassam N, et al,. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol 2010; 16: 2323-30.
-
(2010)
World J Gastroenterol
, vol.16
, pp. 2323-2330
-
-
Thomson, A.B.1
Sauve, M.D.2
Kassam, N.3
-
32
-
-
84903627362
-
Neuroendocrine pathology of the stomach: The Parma contribution
-
Bordi C,. Neuroendocrine pathology of the stomach: the Parma contribution. Endocr Pathol 2014; 25: 171-80.
-
(2014)
Endocr Pathol
, vol.25
, pp. 171-180
-
-
Bordi, C.1
-
33
-
-
67651097918
-
Clinical use of proton-pump inhibitors but not H2-blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen i and pepsinogen II in a random adult population
-
Agréus L, Storskrub T, Aro P, et al,. Clinical use of proton-pump inhibitors but not H2-blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen I and pepsinogen II in a random adult population. Scand J Gastroenterol 2009; 44: 564-70.
-
(2009)
Scand J Gastroenterol
, vol.44
, pp. 564-570
-
-
Agréus, L.1
Storskrub, T.2
Aro, P.3
|